The effects of darbepoetin on peritoneal fibrosis induced by chemical peritonitis and on peritoneal tissue MMP-2 and TIMP-2 levels in rats

European Journal of Inflammation

Volumn 7, Issue 2, 2009, Pages 87-95

  Borazan, Ali ^a   Camsari, T ^b   Cavdar, Z ^b   Sarioglu, S ^b   Yilmaz, O ^b   Oktay, G ^b   Sifil, A ^b   Celik, A ^b   Cavdar, C ^b   Aysal, A ^b   Kolatan, E ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

MMP 2; Peritoneal fibrosis; TIMP 2

Indexed keywords

ALCOHOL; CHLORHEXIDINE GLUCONATE; EOSIN; GELATINASE A; HEMATOXYLIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROSCOPY; NONHUMAN; PERITONEAL FIBROSIS; PERITONITIS; PROTEIN EXPRESSION; RAT; STAINING; VASCULAR DISEASE; WISTAR ALBINO GLAXO RAT; ZYMOGRAPHY;

EID: 69549112684     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727x0900700205     Document Type: Article

References (30)

1. Krediet RT. 30 years of peritoneal dialysis development: the past and the future. Perit Dial Int 2007; 27:S35-41.
2. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis - a multicentre study in Japan. Nephrol Dial Transplant 2007; 22:560-567 (Pubitemid 46189902)
3. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23:530-541 (Pubitemid 37527296)
4. Miyata T, Devusyst O, Kurukowa K, Van Ypersele de Strihou C. Toward better dialysis compatibility advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61:375-386 (Pubitemid 34102577)
5. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-479 (Pubitemid 34106290)
6. Heimburger O, Waniewski J, Werynski A, Tranaeus A. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506. (Pubitemid 20258753)
7. Hirahara I, Umeyama K, Shofuda K, et al. Increase of matrix metalloproteinase-2 in dialysate of rat sclerosing encapsulating peritoneal model. Nephrology 2002; 7:161-169 (Pubitemid 35015367)
8. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 2006; 69:562-573 (Pubitemid 43139720)
9. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69:1806-1813 (Pubitemid 43739209)
10. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97:10526-10531 (Pubitemid 30707300)
11. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100:802-806 (Pubitemid 36457809)
12. Lee SH, Li C, Lim SW, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005; 25:64-76. (Pubitemid 40529278)
13. Park SH, Choi MJ, Song IK, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 2007; 18:1497-1507
14. Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101:31-39 (Pubitemid 43765334)
15. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110:1006-1012 (Pubitemid 39128626)
16. Ishii Y, Sawada T, Shimizu A, Tojimbara T, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16:1262-1266 (Pubitemid 32547385)
17. Sis B, Sarioglu S, Sokmen S, et al. Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma. J Clin Pathol 2005; 5:32-38 (Pubitemid 40070493)
18. Sarioglu S, Sis B, Celik A, et al. Quantitative digital histochemistry with methenamine silver staining in renal allograft biopsies excluding pure chronic allograft nephropathy cases. Transplant Proc 2006; 38:490-491
19. Sis B, Sarioglu S, Celik A, et al. Renal medullary changers in renal allograft recipients with raised serum creatinine. J Clin Pathol 2006; 59:377-381
20. Sokmen S, Lebe B, Sarioglu S, et al. Prognostic value of CD44 expression in colorectal carcinomas. Anticancer Res 2001; 21:4121-4126 (Pubitemid 34229298)
21. Cohen PA, Gower AC, Stucchi AF, Leeman SE, Becker JM, Reed KL. A neurokinin-1 receptor antagonist that reduces intraabdominal adhesion formation increases peritoneal matrix metalloproteinase activity. Wound Repair Reg 2007; 15:800-808 (Pubitemid 350135234)
22. Wiechelman KJ, Braun RD, Fitzpatrick JD. Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 1988; 175:231-237
23. Kleiner DE, Stetler-Stevenson WG. Quantitative Zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 21:325-329
24. Clark IM, Powell LK, Wright JK, Cawston TE. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 1991; 11:76-85.
25. Ersoy R, Celik A, Yilmaz O, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007; 27:424-431 (Pubitemid 47202195)
26. Martin J, Yung S, Robson RL, Steadman R, Davies M. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit Dial Int 2000; 20:524-533
27. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis Perit Dial Int 2003; 23:530-541
28. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77:863-868
29. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002; 90:251-262
30. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494